Sildenafil citrate: lessons learned from 3 years of clinical experience

• Published in: International journal of impotence research Vol. 14 Suppl 1; no. S1; pp. S43 - S52
• Main Author: Hatzichristou, D G
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.02.2002
• Subjects: Erectile dysfunction; Erectile Dysfunction - drug therapy; Humans; Male; Piperazines - therapeutic use; Product Surveillance, Postmarketing; Prostate cancer; Purines; Sildenafil Citrate; Sulfones; Vasodilator Agents - therapeutic use
• ISSN: 0955-9930; 1476-5489
• DOI: 10.1038/sj.ijir.3900805

In the 3 y since its initial approval, sildenafil has become the most widely used treatment for erectile dysfunction (ED) and has been prescribed to more than 13 million patients worldwide. Significant improvements in erectile function have been demonstrated in double-blind, placebo-controlled studies in diverse patient populations. A significant treatment effect has been shown with sildenafil in men with ED and a history of diabetes, cardiovascular disease, minor depression, spinal cord injury and multiple sclerosis. In addition, promising results have been shown in patients with treated prostate cancer, end-stage renal disease, Parkinson's disease and spina bifida and in multiple-organ transplant recipients. Postmarketing data of the use of sildenafil in clinical practice confirm the efficacy and safety found in clinical trials and high satisfaction with treatment. Public awareness of the common occurrence of ED and the high likelihood of a potentially favorable response to an oral treatment increased dramatically with the introduction of sildenafil. Physicians, however, are still not comfortable with ED management, which negatively affects pharmacotherapy response rates and patients' compliance to treatment. Continuing medical education seems mandatory to overcome existing problems in ED management.